BioSpace News Archive

InMode Ltd. (Nasdaq: INMD ) , a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2022 before the Nasdaq market opens on Thursday, July 28, 2022.

RedHill invited to give prestigious oral presentation of important data detailing high eradication rates across body mass index (BMI) groups with Talicia, the U.S.'s leading brand for Helicobacter pylori (H. pylori) eradication treatment - invitation sent to researchers with significant recently published clinical findings.

ChemImage, a leader in molecular chemical imaging technology, is pleased to announce that the Binational Industrial Research & Development Foundation is investing $950,000 to develop NurseSpace, an innovative medication identification and dispensing system.

Replicate Bioscience , a company pioneering self-replicating RNA (srRNA) therapies for use against cancers, immune and inflammatory disorders, and other diseases, announced today that Zelanna Goldberg, M.D. , will join the company as Chief Medical Officer and Mohit Trikha , Ph.D., will join the company’s Board of Directors, effective immediately.

Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Jessica Meng as the company’s first Chief Commercial Officer.

Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tool for the job, launched new isothermal applications for biologics and gene therapies on its Uncle platform.

Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today the appointment of Stephen Griffin , Ph.D. to Chief Executive Officer, effective immediately.

Incyte announced that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 2, 2022.

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2022 financial results on Tuesday, August 2, 2022.

Quantabio , a leading provider of robust DNA and RNA amplification reagents for the most demanding molecular testing and life science research applications, today announced the commercial availability of the qScript Ultra Flex Kit and the qScript Ultra SuperMix for the synthesis of first-strand complementary DNA (cDNA).